Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer

Pharmacology, Toxicology and Pharmaceutical Science

• Colorectal Cancer 100%
• Protein 80%
• microRNA 80%
• Tumor Suppressor Protein 80%
• Mitogen Activated Protein Kinase Kinase Inhibitor 60%
• Trametinib 60%
• Dabrafenib 60%
• Combination Therapy 40%
• Epidermal Growth Factor Receptor Antibody 40%
• Prognosis 20%
• Epidermal Growth Factor Receptor 20%
• Cetuximab 20%
• Epidermal Growth Factor Receptor Kinase Inhibitor 20%
• Small Interfering RNA 20%
• Carcinogenesis 20%
• Cell Proliferation 20%
• Apoptosis 20%

Biochemistry, Genetics and Molecular Biology

• MicroRNA 80%
• Epidermal Growth Factor Receptor 80%
• MEK Inhibitor 60%
• Trametinib 60%
• Dabrafenib 60%
• Protein 60%
• Cancer Cell 40%
• Mitogen-Activated Protein Kinase 40%
• Antibody 40%
• Electric Potential 20%
• Cell Proliferation 20%
• Phosphorylation 20%
• Apoptosis 20%
• Modulation 20%
• Protein Array 20%
• Antiproliferative Activity 20%
• MAPK Signaling 20%
• Growth Factor Receptor Inhibitor 20%
• Cetuximab 20%
• Small Interfering RNA 20%